----item----
version: 1
id: {C946A7EF-A5AD-444C-9E23-64B63981B4F4}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/03/Janssen seeks to block Celltrions infliximab biosimilar
parent: {B4DD542A-3150-404B-9742-7EB9440DE618}
name: Janssen seeks to block Celltrions infliximab biosimilar
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: f7405282-e5f3-443a-b12e-46220425d75d

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{CD796374-A60A-4D81-8A05-7B92AD2013C1}|{F5161CC2-772F-472E-A21C-BF196343462E}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 56

Janssen seeks to block Celltrion's infliximab biosimilar
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 55

Janssen seeks to block Celltrions infliximab biosimilar
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2893

<p>Johnson & Johnson unit Janssen has filed a lawsuit seeking to block Celltrion from bringing its infliximab biosimilar, known as CTP13, to the US market.</p><p>CTP13 is referenced on Janssen's Remicade, a tumor necrosis factor blocker, which was first approved in the US in 1998.</p><p>Celltrion is seeking the FDA's blessing to market CTP13 as a biosimilar therapy to treat the same indications for which Remicade is approved in the US: Crohn's disease, ulcerative colitis, active rheumatoid arthritis, active ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.</p><p>But in a complaint filed on 6 March at the US District Court for the District of Massachusetts, Janssen is alleging Celltrion failed to follow the requirements set out by the Biologics Price Competition and Innovation Act, which established the abbreviated licensure pathway for biological products demonstrated to be "biosimilar" to or "interchangeable" with an FDA-licensed innovator biologic.</p><p>Janssen also said Celltrion has violated six of the former firm's patents.</p><p>The lawsuit follows a similar one filed by Amgen against Novartis unit Sandoz, which won the FDA's <a href="http://www.scripintelligence.com/home/NovartisSandoz-make-history-with-1st-US-biosimilar-Zarxio-357116" target="_new">approval on 6 March</a> to market the first biosimilar in the US &ndash; Zarxio.</p><p>Sandoz's biosimilar is referenced on Amgen's Neupogen. The FDA approved Zarxio for the same indications Neupogen carries in its labeling.</p><p>The Amgen lawsuit against Sandoz was filed at the US District Court for the Northern District of California. </p><p><b>Related articles</b></p><p><a href="http://www.scripintelligence.com/home/NovartisSandoz-make-history-with-1st-US-biosimilar-Zarxio-357116" target="_new">Novartis/Sandoz make history with 1st US biosimilar Zarxio</a></p><p><a href="http://www.scripintelligence.com/home/Will-FDA-adcomm-be-lucky-for-Celltrion-infliximab-biosimilar-356630" target="_new">Will FDA adcomm be lucky for Celltrion infliximab biosimilar?</a></p><p><a href="http://www.scripintelligence.com/home/First-US-biosimilar-MAb-on-the-horizon-as-Celltrion-files-Remsima-353328" target="_new">First US biosimilar MAb on the horizon as Celltrion files Remsima</a></p><p><a href="http://www.scripintelligence.com/home/comment/FDAs-1st-biosimilar-adcomm-a-lovefest-355994" target="_new">FDA's 1st biosimilar adcomm: a lovefest</a></p><p><a href="http://www.scripintelligence.com/home/NovartisSandoz-biosimilar-1st-to-win-FDA-panel-backing-355993" target="_new">Novartis/Sandoz biosimilar 1st to win FDA panel backing</a></p><p><a href="http://www.scripintelligence.com/home/FDA-No-meaningful-differences-between-Amgens-Neupogen-Sandoz-biosimilar-355934" target="_new">FDA: No 'meaningful' differences between Amgen's Neupogen, Sandoz biosimilar</a></p><p><p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 159

<p>Johnson & Johnson unit Janssen has filed a lawsuit seeking to block Celltrion from bringing its infliximab biosimilar, known as CTP13, to the US market.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 55

Janssen seeks to block Celltrions infliximab biosimilar
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151003T080000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151003T080000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151003T080000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028076
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 56

Janssen seeks to block Celltrion's infliximab biosimilar
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357149
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042308Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

f7405282-e5f3-443a-b12e-46220425d75d
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042308Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
